Allogene Therapeutics ALLO Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -52.3%+1.1pp | -53.4%+1.0pp | -54.4%+0.7pp | -55.1%+4.5pp | -59.6%-4.5pp | |
| Return on invested capital | -51.3%+5.1pp | -56.5%-2.8pp | -53.7%+10.1pp | -63.8%-5.2pp | -58.6%-0.6pp | |
| Liquidity | ||||||
| Current ratio | 9.6×+1.7× | 7.9×-0.3× | 8.2×-0.7× | 8.9×-0.8× | 9.7×+1.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.2×0.0× | |
| Per Share | ||||||
| Book value per share | $1.16-12.5% | $1.33-6.6% | $1.42-9.8% | $1.57-12.1% | $1.79-17.4% | |
| Valuation | ||||||
| Market capitalization | $711.02M+164% | $307.88M+11.9% | $275.13M+0.6% | $273.41M-13.8% | $317.21M-29.0% | |
| Price / book | 2.5×+1.9× | 1.1×+0.2× | 0.9×+0.1× | 0.8×0.0× | 0.8×-0.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Allogene Therapeutics's ratios come from?
- Every ratio is computed from Allogene Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.